DrugBiological
Melanocyte Protein PMEL clinical trials
Counted the way a researcher would: Melanocyte Protein PMEL with its salts, dosage forms, brands and biosimilars.
This browser remembers your choice.
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1998 | 1 |
| 2004 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 3
National Cancer Institute (NCI) (3) · Bristol-Myers Squibb (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Melanocyte Protein PMEL is read from its arms, and is right about nine times in ten.
Testing it · 4
- Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00080353Written as gp100:209-217
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT00094653Written as MDX-1379 (gp100) Melanoma Peptide Vaccine
- A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's AdjuvantCompletedPhase 1National Cancer Institute (NCI)NCT00001439Written as gp100 human melanoma peptide
- Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal SequenceCompletedPhase 2National Cancer Institute (NCI)NCT00001705Written as GP100 peptide